To drive collaboration to control cost, reduce waste and maximize effectiveness of specialty drugs, the National Alliance and its member coalitions have developed stakeholder guidelines and an engagement framework targeting critical issues and opportunities for specialty stakeholders including manufacturers, providers, health plans, and pharmacy benefit managers.
Titled “The Five Rights Framework”, these guidelines are meant to bring all healthcare stakeholders to the table to improve value for healthcare purchasers and work towards delivering the best possible patient care. The Framework includes: Right Drug, Right Price, Right Place, Right Data and Right Support.
Development of a “Collective Agenda”
- Clinical efficacy and safety independent of conflicted interests
- Support improved assessment of correct drug, dose and duration of treatment for specific patient
- Expand purchaser transparency and engagement and use of National Drug Codes (NDCs)
- Value based contracting aligned with performance and adherence to high value drugs
- Cost parity or benefit differentials across sites of care for same drugs and services
- Effective emotional and social support to increase adherence and improve outcomes
- Discontinue conflicting practices - low value coupon programs, drug increases in excess of CPI, exclusion of high value delivery options
This collective agenda has been integrated into our 2018 PBM Assessment as well as our Oncology Deep Dive Assessment. This will continue to be a major focus of our broader Value Based Marketplace agenda.
Looking for more information?
View 2017 Press Release
Download the infographic here!